NO20002945L - Stabiliserte teriparatidoppløsninger - Google Patents

Stabiliserte teriparatidoppløsninger

Info

Publication number
NO20002945L
NO20002945L NO20002945A NO20002945A NO20002945L NO 20002945 L NO20002945 L NO 20002945L NO 20002945 A NO20002945 A NO 20002945A NO 20002945 A NO20002945 A NO 20002945A NO 20002945 L NO20002945 L NO 20002945L
Authority
NO
Norway
Prior art keywords
stabilized teriparatide
solutions
teriparatide solutions
stabilized
teriparatide
Prior art date
Application number
NO20002945A
Other languages
English (en)
Other versions
NO327302B1 (no
NO20002945D0 (no
Inventor
Chin-Ming Chang
Henry Acken Havel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002945(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20002945D0 publication Critical patent/NO20002945D0/no
Publication of NO20002945L publication Critical patent/NO20002945L/no
Publication of NO327302B1 publication Critical patent/NO327302B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
NO20002945A 1997-12-09 2000-06-08 Lagringsstabil sammensetning, forseglet ror eller patron inneholdende nevnte sammensetning samt fremgangsmate for deres fremstilling NO327302B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09
PCT/US1998/026043 WO1999029337A1 (en) 1997-12-09 1998-12-08 Stabilized teriparatide solutions

Publications (3)

Publication Number Publication Date
NO20002945D0 NO20002945D0 (no) 2000-06-08
NO20002945L true NO20002945L (no) 2000-07-07
NO327302B1 NO327302B1 (no) 2009-06-02

Family

ID=22086574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002945A NO327302B1 (no) 1997-12-09 2000-06-08 Lagringsstabil sammensetning, forseglet ror eller patron inneholdende nevnte sammensetning samt fremgangsmate for deres fremstilling

Country Status (31)

Country Link
EP (2) EP1417972B2 (no)
JP (1) JP4405666B2 (no)
KR (1) KR100482703B1 (no)
CN (1) CN1198644C (no)
AR (1) AR018526A1 (no)
AT (1) ATE260113T1 (no)
AU (1) AU759726B2 (no)
BR (1) BR9813463A (no)
CA (1) CA2314313C (no)
CY (1) CY1114000T1 (no)
CZ (1) CZ302401B6 (no)
DE (1) DE69821872T2 (no)
DK (2) DK1417972T4 (no)
EA (1) EA004761B1 (no)
EG (1) EG23675A (no)
ES (2) ES2405994T5 (no)
HU (1) HU230784B1 (no)
ID (1) ID27741A (no)
IL (1) IL136662A (no)
MY (1) MY120063A (no)
NO (1) NO327302B1 (no)
NZ (1) NZ505222A (no)
PE (1) PE20000001A1 (no)
PL (1) PL194268B1 (no)
PT (2) PT1417972E (no)
SK (1) SK288203B6 (no)
TR (1) TR200002134T2 (no)
TW (1) TW570811B (no)
UA (1) UA72884C2 (no)
WO (1) WO1999029337A1 (no)
ZA (1) ZA9811127B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
IL147731A0 (en) * 2000-05-19 2002-08-14 Bionebraska Inc Peptide pharmaceutical formulations
NZ523457A (en) * 2000-06-30 2004-11-26 Daiichi Suntory Pharma Co Composition for stimulating bone formation comprising hPTH in which the acetic acid component is low enough for administration to the nasal mucosa
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
EP1444263A4 (en) * 2001-11-05 2005-04-20 Lilly Co Eli METHOD FOR IMPROVING THE STABILITY OF A BONE BINDING IMPLANT
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
EP1638595B1 (en) 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
CA2628945A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
KR20190095552A (ko) * 2009-09-09 2019-08-14 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 pth가 주 1회 투여되는 것을 특징으로 하는, pth 함유 골다공증 치료/예방제
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
MY208384A (en) 2016-03-01 2025-05-05 Ascendis Pharma Bone Diseases As Pth prodrugs
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
KR102627405B1 (ko) 2016-09-29 2024-01-18 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形性形態
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
CA3075984C (en) * 2017-09-22 2024-10-01 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT PHARMACOKINETIC AND/OR SAFETY PROPERTIES
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 N-ホルミルピぺリジン含有量が低減されている、及び/又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
MY209748A (en) * 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー/エス 医薬製剤
EP4110370A4 (en) * 2020-03-30 2023-06-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. HUMAN PARATHYROID HORMONE (PTH) FORMULATIONS AND METHODS OF PRODUCING THEM
JP2024521399A (ja) 2021-06-10 2024-05-31 ニューレリス、インク. 小児患者における発作性障害を治療するための組成物および方法
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 h―PTH(1―34)凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
CZ20002115A3 (en) 2001-05-16
EP0920873A2 (en) 1999-06-09
DK1417972T3 (da) 2013-05-13
HUP0004447A2 (hu) 2001-04-28
CZ302401B6 (cs) 2011-05-04
NZ505222A (en) 2003-05-30
TR200002134T2 (tr) 2000-11-21
JP4405666B2 (ja) 2010-01-27
BR9813463A (pt) 2000-10-10
EA004761B1 (ru) 2004-08-26
EA200000629A1 (ru) 2000-12-25
ES2405994T5 (es) 2019-01-30
CN1281370A (zh) 2001-01-24
IL136662A (en) 2004-09-27
HK1021798A1 (en) 2000-07-07
EP0920873B1 (en) 2004-02-25
PT920873E (pt) 2004-06-30
MY120063A (en) 2005-08-30
IL136662A0 (en) 2001-06-14
ES2215268T3 (es) 2004-10-01
KR100482703B1 (ko) 2005-04-14
ID27741A (id) 2001-04-26
PL340902A1 (en) 2001-03-12
EG23675A (en) 2007-04-15
DE69821872T2 (de) 2005-01-05
TW570811B (en) 2004-01-11
UA72884C2 (uk) 2005-05-16
EP1417972B1 (en) 2013-04-10
EP0920873A3 (en) 1999-08-04
CA2314313A1 (en) 1999-06-17
SK288203B6 (sk) 2014-07-02
KR20010032881A (ko) 2001-04-25
PE20000001A1 (es) 2000-01-17
PT1417972E (pt) 2013-05-24
AU1717799A (en) 2005-05-16
AU759726B2 (en) 2003-04-17
JP2001525372A (ja) 2001-12-11
ATE260113T1 (de) 2004-03-15
HUP0004447A3 (en) 2003-06-30
DE69821872D1 (de) 2004-04-01
EP1417972A1 (en) 2004-05-12
DK1417972T4 (en) 2018-10-22
SK15322000A3 (sk) 2001-05-10
PL194268B1 (pl) 2007-05-31
CY1114000T1 (el) 2016-07-27
DK0920873T3 (da) 2004-06-28
ZA9811127B (en) 2000-07-11
NO327302B1 (no) 2009-06-02
CA2314313C (en) 2005-02-08
HU230784B1 (en) 2018-05-02
CN1198644C (zh) 2005-04-27
ES2405994T3 (es) 2013-06-04
EP1417972B2 (en) 2018-08-22
NO20002945D0 (no) 2000-06-08
WO1999029337A1 (en) 1999-06-17
AR018526A1 (es) 2001-11-28

Similar Documents

Publication Publication Date Title
DK0920873T3 (da) Stabiliserede teriparatidoplösninger
NO20003131D0 (no) Krystallinsk teriparatid
DE69826749D1 (de) Stabilisierte Persäurelösungen
ID22500A (id) Turunan sulfonamida
ID24430A (id) Turunan-turunan benzamidina
NO2006014I1 (no) Insulin glulisin
ID24529A (id) Turunan-turunan 9-oksima eritromisin
DE59804393D1 (de) Luftleiteinrichtung
FI973171A0 (fi) Foerfarande foer drift av arbetsfartyg
NO20002555L (no) Skjøt
DE69815673D1 (de) Stabilisierte hydroxylaminlösungen
IT1304161B1 (it) Stiratoio
ID20897A (id) Susunan penutup-rapat
FI973961A0 (fi) Lyft- och belastningsanordning foer en valsstapel i en kalander
DE69734891D1 (de) Ausrichtvorrichtung
FI972138A0 (fi) Returtraog i bestrykningsanordning
FR2770103B1 (fr) Bigoudi perfectionne
ID21138A (id) Teknologi film-tipis untuk head-drum
KR980001295U (ko) 개량 도장
FI974242A0 (fi) Formframstaellning av plywoodprofil i kontinuerlig drift
BR7700789U (pt) Prumo
FI971698A0 (fi) Klingstyrenhet i en cirkelsaog
FI971123A0 (fi) Foervarings- och transportredskap i synnerhet foer pappersprodukter
FI974635A0 (fi) I vaermebatteri integrerbar ventilkonstruktion
FI974354A0 (fi) Kvaevereducering i avloppsvatten

Legal Events

Date Code Title Description
MK1K Patent expired